#### (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

#### **Equivalent or Equal Terms**

- And, with (used in histology rules, i.e. duct and lobular is equivalent to duct with lobular)
- Duct, ductal
- Mammary, breast
- Mucinous, colloid
- NOS, NST
- Tumor, mass, lesion, neoplasm

#### Synonyms for "in situ"

- Behavior code '2'
- DCIS
- Intracystic
- Intraductal
- Noninfiltrating
- Noninvasive

#### **Definitions**

Carcinoma with osteoclast-like giant cells (8035): This is a specific type of duct carcinoma. The carcinomatous part of the lesion is most commonly an infiltrating duct carcinoma.

**Ductular carcinoma (8521):** A malignancy that is infrequently found in the breast and may be found with greater frequency in other organs such as pancreas or prostate. Code 8521 is seldom, if ever, applied to the breast. Although the ICD-O-3 suggests that 8521 is a site-associated code; the addition of (C50.\_) after this code may be misleading. The WHO Histological Classification of Tumours of the Breast does not list 8521, ductular carcinoma.

**Duct carcinoma, NOS (8500):** The largest group of breast cancers. Duct carcinoma, NOS is not a specific histologic type because it lacks specific features that can be used to better classify the tumor. See Table 1 and Table 2 for intraductal and duct types.

(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

**Inflammatory breast carcinoma (IBC):** A breast cancer with a distinctive clinical presentation believed to be due to lymphatic obstruction from an underlying invasive adenocarcinoma. The vast majority of cases have a prominent dermal lymphatic infiltration by tumor. Dermal lymphatic infiltration without the characteristic clinical picture is insufficient to qualify as inflammatory carcinoma.

**Intracystic carcinoma/Intracystic papillary carcinoma:** Variant of intraductal carcinoma used to describe encysted forms of papillary carcinoma. Code intracystic carcinoma as in situ /2 unless the histology is described as invasive intracystic carcinoma.

In Situ: A tumor that is confined to the duct system (ductular or lobular) and does not invade surrounding stroma.

**Invasive:** A tumor that penetrates beyond the ductal basement membrane into the adjacent stroma of the breast parenchyma.

**Lobular Carcinoma:** Lobular carcinoma includes solid and alveolar patterns. About 5 to 10% of breast cancers are lobular. There is about a 20% chance that the opposite breast will also be involved, and many of them arise multicentrically in the same breast.

**Paget Disease:** Paget disease of the nipple is a condition where the epidermis of the nipple is infiltrated with neoplastic cells. ICD-O-3 classifies all mammary Paget disease as a malignant process with a malignant behavior (/3). Under the matrix system, only if the Paget disease is explicitly specified as in situ or non-invasive by the pathologist, code the behavior in situ (/2).

**Phyllodes tumor (cystosarcoma phyllodes):** A rare tumor with incidence ranging from 0.3% to 0.9% of all breast cancers. These tumors have a natural history and clinical behavior different from carcinoma of the breast. Criteria to classify benign, borderline and malignant cystosarcoma phyllodes utilize histologic parameters such as cellular atypia, mitotic activity and tumor margins. The reported incidence of malignant cystosarcoma phyllodes is approximately 25% of all phyllodes tumors.

Pleomorphic carcinoma (8022): This is a specific duct carcinoma type; A rare variant of high grade ductal carcinoma, NOS.

**Sarcoma of breast:** Primary sarcomas of the breast are rare accounting for less than 0.1% of all malignant tumors of the breast. Diagnoses may include fibrosarcoma, angiosarcoma, pleomorphic sarcoma, leiomyosarcoma, myxofibrosarcoma, hemangiopericytoma, and osteosarcoma (extra-osseous osteosarcoma of breast).

**Scirrhous Carcinoma:** An adenocarcinoma with a firm-hard nodule associated with a dense connective tissue in the stroma. Scirrhous carcinoma is descriptive term, not a specific type of ductal carcinoma.

(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

#### Table 1 – Intraductal (8500/2) and Specific Intraductal Carcinomas

*Note*: These are the most common specific intraductal carcinomas. This is not intended to be a complete list of all possible intraductal types. If a histology appears only on table 1, it does not mean that it is impossible for that histology to occur with a malignant behavior (/3).

Column 1:	Column 2:
Code	Type
8201	Cribriform
8230	Solid
8401	Apocrine
8500	Intraductal, NOS
8501	Comedo
8503	Papillary
8504	Intracystic carcinoma
8507	Micropapillary/Clinging

#### Table 2 – Duct (8500/3) and Specific Duct Carcinomas

*Note*: These are the most common specific duct carcinomas. This is not intended to be a complete list of all possible duct types. If a histology appears only on table 2, it does not mean that it is impossible for that histology to occur with an in situ behavior (/2).

Column 1:	Column 2:
Code	Туре
8022	Pleomorphic carcinoma
8035	Carcinoma with osteoclast-like giant cells
8500	Duct, NOS
8501	Comedocarcinoma
8502	Secretory carcinoma of breast
8503	Intraductal papillary adenocarcinoma with invasion
8508	Cystic hypersecretory carcinoma

(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

#### Table 3 - Combination Codes for Breast Cancers

Use this **two-page** table with rules H5, H6, H7, H8, H16, H17, H18, H19, H24, H25, H26 and H28 to select combination histology codes. Compare the terms in the diagnosis to the terms in Columns 1 and 2. If the terms match, code the case using the ICD-O-3 histology code in column 4. Use the combination codes listed in this table only when the histologies in the tumor match the histologies listed below.


Column 1: Required Histology	Column 2: Combined with Histology	Column 3: Combination Term	Column 4: Code
Any combination excluding lobular and duct histologies from Tables 1 and 2	Other than ductal and lobular	Adenocarcinoma with mixed subtypes*	8255/3*
Intraductal carcinoma and	Lobular carcinoma in situ	Intraductal carcinoma and lobular carcinoma in situ	8522/2
Infiltrating duct and	Infiltrating lobular carcinoma	Infiltrating duct and lobular carcinoma	8522/3
Intraductal and <b>two or more</b> of the histologies in Column 2 OR	Cribriform Solid	Intraductal mixed with other types of carcinoma	8523/2
<b>two or more</b> of the histologies in	Apocrine		
Column 2	Papillary	1	
	Micropapillary		
	Clinging		
Infiltrating duct and one or more	Tubular	Infiltrating duct mixed with other types of carcinoma	8523/3
of the histologies in Column 2	Apocrine		
	Mucinous		
	Secretory carcinoma		
	Intraductal papillary adenocarcinoma with invasion		
	Intracystic carcinoma, NOS		
	Medullary	7	
Table 3 continues on the next page		•	•

### (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

Column 1:	Column 2:	Column 3:	Column 4:
Required Histology	Combined with Histology	Combination Term	Code
Table 3 continued			
Infiltrating lobular carcinoma and	Tubular	Infiltrating lobular mixed with other types of	8524/3
	Apocrine	carcinoma	
	Mucinous	<i>Note:</i> Invasive carcinomas only. Do not use this	
	Secretory carcinoma	code for in situ	
	Intraductal papillary adenocarcinoma with		
	invasion		
	Intracystic carcinoma, NOS		
	Medullary		
	Paget disease (NOS and invasive)		
Paget disease and	Infiltrating duct carcinoma (includes any	Paget disease and infiltrating duct carcinoma	8541/3
	specific duct type listed in Table 2		
Paget disease and	Intraductal carcinoma (includes any specific	Paget disease and intraductal carcinoma	8543/3
	intraductal type in Table 1)		

<sup>\*</sup>Rarely used for breast cancer

### Breast Equivalent Terms, Definitions, Tables and Illustrations C500-C509 (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)






Netter illustration used with permission of Elsevier Inc. All rights reserved

### (Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

#### Mammary Gland



Atlas of Human Anatomy -- Frank H. Netter

Netter illustration used with permission of Elsevier Inc. All rights reserved